Collagen I-based scaffolds negatively impact fracture healing in a mouse-osteotomy-model although used routinely in research and clinical application


  • A. Lang
  • M. Kirchner
  • J. Stefanowski
  • M. Durst
  • M.C. Weber
  • M. Pfeiffenberger
  • A. Damerau
  • A.E. Hauser
  • P. Hoff
  • G.N. Duda
  • F. Buttgereit
  • K. Schmidt-Bleek
  • T. Gaber


  • Acta Biomaterialia


  • Acta Biomater 86: 171-184


  • Although several biomaterials for bone regeneration have been developed in the last decades, clinical application of bone morphogenetic protein 2 is clinically only approved when applied on an absorbable bovine collagen I scaffold (ACS) (Helistat; ACS-H). In research, another ACS, namely Lyostypt (ACS-L) is frequently used as a scaffold in bone-linked studies. Nevertheless, until today, the influence of ACS alone on bone healing remains unknown. Unexpectedly, in vitro studies using ASC-H revealed a suppression of osteogenic differentiation and a significant reduction of cell vitality when compared to ASC-L. In mice, we observed a significant delay in bone healing when applying ACS-L in the fracture gap during femoral osteotomy. The results of our study show for the first time a negative influence of both ACS-H and ACS-L on bone formation demonstrating a substantial need for more sophisticated delivery systems for local stimulation of bone healing in both clinical application and research.